



Atty. Dkt. No. 089048-0299

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jhi-Joung WANG
Title: NOVEL ESTER DERIVATIVES OF BUPRENORPHINE
AND THEIR PREPARATION PROCESSES, AND
LONG ACTING ANALGESIC PHARMACEUTICAL
COMPOSITIONS
Appl. No.: 10/645,557
Filing Date: August 22, 2003
Examiner: Not yet assigned
Art Unit: Not yet assigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop PATENT APPLICATION
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

The USPTO has waived the requirement under 37 CFR 1.98(a)(2)(i) to submit copies of U.S. patents and U.S. patent application publications when citing and submitting an Information Disclosure Statements in a patent application filed after June 30, 2003 and in an international application that has entered the national stage under 37 USC §371 after June 30, 2003. Accordingly, copies of these types of documents are not being supplied in connection with this application. Reference is being made to Pre-OG Notice from Office of Patent Legal Administration dated July 25, 2003, *Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003*.

Applicant submits herewith on Form PTO 1449 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 10/291,614, filed 11/12/2002. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application. Additionally, five new references are being submitted herewith. Copies of these newly cited references are submitted herewith.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is

considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicant respectfully requests that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,


Date 22 September 2007

By S. A. Bent

FOLEY & LARDNER
Customer Number: 22428
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

Stephen A. Bent
Attorney for Applicant
Registration No. 29,768

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 089048-0299		SERIAL NO. 10/645,557	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT Jhi-Joung WANG			
				FILING DATE 08/22/03		GROUP ART UNIT	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
		3,433,791	03/18/1969	Bentley et al.			
		6,004,969	12/21/1999	Hu			
		5,750,534	05/12/1998	Yoa-Pu et al.			
		6,225,321 B1	05/01/2001	Hu et al.			
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
		WO 96/28451	9/19/96	PCT	C07D	489/02	
		WO 96/16063	5/30/96	PCT	C07D	489/02	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Hayes et al., "Determination of Receptors that Mediate Opiate Side Effects in the Mouse", Br. J. Pharmac. (1983), 79, 731-736.						
	Baxter et al., "Prevention of Epidural Morphine-induced Respiratory Depression with Intravenous Nalbuphine Infusion in Post-Thoracotomy Patients", Canadian Journal of Anaesthesia (1989) 36:5, pp. 503-509.						
	Bickel et al., "A Clinical Trial of Buprenorphine: Comparison with Methadone in the Detoxification of Heroin Addicts", Clinical Pharmacology Therapeutics, January, 1988, Vol. 43, No. 1, pp. 72-78.						
	Fudala et al., "Use of Buprenorphine in the Treatment of Opioid Addiction. II. Physiologic and Behavioral Effects of Daily and Alternate-day Administration and Abrupt Withdrawal", Clinical Pharmacology Therapeutics, April 1990, Vol 47, No. 4, pp. 525-534.						
	Imoto et al., "Transdermal Prodrug Concepts: Permeation of Buprenorphine and Its Alkyl Esters through Hairless Mouse Skin and Influence of Vehicles", Biological Pharmaceutical Bulletin, February 1996, Vol. 19, No. 2 pp. 263-267.						
	Stinchcomb et al., "Permeation of Buprenorphine and its 3-Alkyl-Ester Prodrugs Through Human Skin", Pharmaceutical Research, Vol. 13, No. 10., pp. 1519-1523.						
	Kuhlman et al., "Human Pharmacokinetics of Intravenous, Sublingual, and Buccal Buprenorphine", Journal of Analytical Toxicology, October, 1996, Vol. 20, No. 6, pp. 337-516.						
	Stinchcomb et al., "A Solubility and Related Physicochemical Property Comparison of Buprenorphine and Its 3-Alkyl Esters", Pharmaceutical Research,						

002.1078992